dendrimer docetaxel (DEP docetaxel) / Starpharma - LARVOL DELTA

Starpharma Receives $5.5M R&D Tax Incentive Refund (Starpharma Press Release) - "Starpharma...today announces that it has received a $5.5M Research and Development (R&D) Tax Incentive refund for the 2024 financial year. The refund is associated with eligible R&D activities across Starpharma’s portfolio, including the company’s DEP drug delivery programs and VIRALEZE....The Australian Government's R&D Tax Incentive program provides a refundable tax offset to companies such as Starpharma that are undertaking eligible R&D activities. This initiative aims to encourage investment in R&D, fuelling innovation and ultimately boosting Australia's global competitiveness, driving economic growth and creating job opportunities."

Financing • Breast Cancer • Castration-Resistant Prostate Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Infectious Disease • Metastatic Castration-Resistant Prostate Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Quarterly Activities Report & Appendix 4C (ASX Announcement) (Starpharma Press Release) - "In the May 2024 business update, Starpharma announced plans to advance its DEP HER2 radiodiagnostic candidate towards a first-in-human clinical study in 2025. Additionally, the Company presented a scientific poster at the SNMMI Annual Meeting in Toronto, Canada, in June 2024, highlighting the promising utility of dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications....Net operating cash outflows for Q4 FY24 were $3.0 million, including research and development (R&D) costs of $1.8 million. As expected, the June quarter outflows decreased from Q3, which had R&D costs of $3.3 million. The Q3 costs included clinical trial close-out expenses associated with the completion of the DEP cabazitaxel, DEP docetaxel, and Viraleze clinical programs."

Commercial • New trial • Oncology • Solid Tumor

Half Yearly Report and Accounts (ASX Announcement) (Starpharma Press Release) - "Starpharma...releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24)....The half-year loss after tax was $1.0M (H1 FY23: $8.3M) and includes research and product development expenses of $5.3M (H1 FY23: $5.6M) net of the Australian Government’s R&D tax incentive. Research expenditures were primarily associated with Starpharma’s internal DEP drug delivery programs, including DEP docetaxel, DEP cabazitaxel, DEP irinotecan, DEP ADCs and DEP radiotheranostics, and the Viraleze post-market study."

Commercial • Breast Cancer • Gastrointestinal Cancer • Infectious Disease • Oncology • Pancreatic Cancer • Solid Tumor